Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab and combination lipid-lowering therapy in ACS patients undergoing PCI
NCT05661552Phase 4Completed
- Sponsor
- Yonsei University
- Start
- Dec 2022
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of evolocumab in hypercholesterolemia (2 arms), sponsored by Yonsei University. Primary endpoint: Percent change in LDL level at 2 weeks. Started Dec 2022; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05661552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05661552.